ADVANCEMENTS IN TREATMENT STRATEGIES FOR ANDROGENETIC ALOPECIA: NOVEL THERAPIES AND FUTURE PERSPECTIVES
Abstract
Introduction and Purpose: Androgenetic alopecia (AGA), or male pattern hair loss (MPHL) and female pattern hair loss (FPHL), is the most common form of progressive hair loss, significantly affecting men and women. FDA-approved treatments, such as minoxidil and finasteride, have limitations, including side effects and variable efficacy, highlighting the need for innovative solutions. Recent advancements introduce therapies targeting AGA’s mechanisms, offering hope for improved management.
Materials and Methods: A comprehensive literature review was conducted using PubMed, Web of Science, Embase, and Google Scholar. The search included keywords such as “androgenetic alopecia,” “male pattern hair loss,” “female pattern hair loss,” “minoxidil,” “finasteride,” “dutasteride mesotherapy,” “platelet-rich plasma” and “botulinum toxin.” Articles from the last five years were prioritized.
State of Knowledge: Emerging therapies include low-dose oral minoxidil, topical finasteride, platelet-rich plasma (PRP), mesotherapy, low-level laser therapy (LLLT), and botulinum toxin, offering improved adherence and fewer side effects. Experimental approaches, such as clascoterone, pyrilutamide, and stem cell-based therapies, focus on follicular regeneration and androgen receptor modulation. Advanced technologies like PROTAC and AI-driven designs aim for precision and minimal invasiveness. However, variability in studies and the lack of standardized protocols limit generalizability.
Conclusions: Recent advancements in AGA therapies demonstrate significant potential, offering individualized, effective, and minimally invasive options. Standardized protocols and large-scale trials remain essential to validate efficacy and safety, paving the way for precision medicine in AGA management.
References
Lolli F, Pallotti F, Rossi A, et al. Androgenetic alopecia: a review. Endocrine. 2017;57(1):9-17. doi:https://doi.org/10.1007/s12020-017-1280-y
Severi G, Sinclair R, Hopper JL, et al. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. The British journal of dermatology. 2003;149(6):1207-1213. doi:https://doi.org/10.1111/j.1365-2133.2003.05565.x
Starace M, Orlando G, Alessandrini A, Piraccini BM. Female Androgenetic Alopecia: An Update on Diagnosis and Management. American Journal of Clinical Dermatology. 2019;21(1):69-84. doi:https://doi.org/10.1007/s40257-019-00479-x
Gupta M, Mysore V. Classifications of patterned hair loss: a review. Journal of Cutaneous and Aesthetic Surgery. 2016;9(1):3. doi:https://doi.org/10.4103/0974-2077.178536
Cranwell W, Sinclair R. Male Androgenetic Alopecia. PubMed. Published 2000. https://pubmed.ncbi.nlm.nih.gov/25905192/
Stradczuk M, Mazurek Ł, Rękas B, et al. How to treat androgenetic alopecia – the most common form of hair loss. A review. Journal of Education Health and Sport. 2024;73(73):51729-51729. doi:https://doi.org/10.12775/jehs.2024.73.51729
Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023;83(8):701-715. doi:https://doi.org/10.1007/s4026502301880x
Hoffmann R, Happle R. Current understanding of androgenetic alopecia. Part I: etiopathogenesis. European journal of dermatology: EJD. 2000;10(4):319-327. https://pubmed.ncbi.nlm.nih.gov/10846263/
Katzer T, Leite Junior A, Beck R, da Silva C. Physiopathology and current treatments of androgenetic alopecia: Going beyond androgens and anti‐androgens. Dermatologic Therapy. 2019;32(5). doi:https://doi.org/10.1111/dth.13059
Alexander SE, Gatto B, Knowles OE, et al. Bioavailable testosterone and androgen receptor activation, but not total testosterone, are associated with muscle mass and strength in females. The Journal of Physiology. Published online October 11, 2024. doi:https://doi.org/10.1113/jp286803
Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5α-Reductase Deficiency in Man: An Inherited Form of Male Pseudohermaphroditism. Science. 1974;186(4170):1213-1215. doi:https://doi.org/10.1126/science.186.4170.1213
Futterweit W, Dunaif A, Yeh HC, Kingsley P. The prevalence of hyperandrogenism in 109 consecutive female patients with diffuse alopecia. Journal of the American Academy of Dermatology. 1988;19(5):831-836. doi:https://doi.org/10.1016/s0190-9622(88)70241-8
Ye W, Xie T, Song Y, Zhou L. The role of androgen and its related signals in PCOS. Journal of Cellular and Molecular Medicine. 2020;25(4):1825-1837. doi:https://doi.org/10.1111/jcmm.16205
Ramos PM, Miot HA. Female Pattern Hair Loss: a clinical and pathophysiological review. Anais Brasileiros de Dermatologia. 2015;90(4):529-543. doi:https://doi.org/10.1590/abd1806-4841.20153370
Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nature Reviews Disease Primers. 2017;3(1). doi:https://doi.org/10.1038/nrdp.2017.11
Zhou C, Li X, Wang C, Zhang J. Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management. Clinical Reviews in Allergy & Immunology. 2021;61(3):403-423. doi:https://doi.org/10.1007/s12016-021-08883-0
Rexbye H, Petersen I, Iachina M, et al. Hair Loss Among Elderly Men: Etiology and Impact on Perceived Age. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2005;60(8):1077-1082. doi:https://doi.org/10.1093/gerona/60.8.1077
Heath AC, Nyholt DR, Gillespie NA, Martin NG. Genetic Basis of Male Pattern Baldness. Journal of Investigative Dermatology. 2003;121(6):1561-1564. doi:https://doi.org/10.1111/j.1523-1747.2003.12615.x
Cuevas-Diaz Duran R, Martinez-Ledesma E, Garcia-Garcia M, et al. The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia. International Journal of Molecular Sciences. 2024;25(5):2542. doi:https://doi.org/10.3390/ijms25052542
Siah T, Muir-Green L, Shapiro J. Female pattern hair loss: A retrospective study in a tertiary referral center. International Journal of Trichology. 2016;8(2):57. doi:https://doi.org/10.4103/0974-7753.188033
Śliwa K, Synia D, Placek W, Agnieszka Owczarczyk-Saczonek. The diagnosis and treatment of androgenetic alopecia: a review of the most current management. Forum Dermatologicum. 2023;9(3):99-111. doi:https://doi.org/10.5603/fd.95391
Badri T, Nessel TA, Kumar D D. Minoxidil. PubMed. Published 2020. https://www.ncbi.nlm.nih.gov/books/NBK482378/
Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Design, Development and Therapy. 2019;Volume 13:2777-2786. doi:https://doi.org/10.2147/dddt.s214907
Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. International Journal of Women’s Dermatology. 2018;4(4):203-211. doi:https://doi.org/10.1016/j.ijwd.2018.05.001
Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. Journal of Dermatological Treatment. 2021;33(4):1-11. doi:https://doi.org/10.1080/09546634.2021.1945527
Ramírez-Marín H, Tosti A. Role of oral minoxidil in patterned hair loss. Indian Dermatology Online Journal. 2022;13(6):729. doi:https://doi.org/10.4103/idoj.idoj_246_22
Gupta AK, Talukder M, Shemar A, Piraccini BM, Tosti A. Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disorders. 2023;9(6):423-437. doi:https://doi.org/10.1159/000531890
Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial. Journal of the American Academy of Dermatology. 2020;82(1):252-253. doi:https://doi.org/10.1016/j.jaad.2019.08.060
Vastarella M, Cantelli M, Patrì A, Annunziata MC, Nappa P, Fabbrocini G. Efficacy and safety of oral minoxidil in female androgenetic alopecia. Dermatologic Therapy. 2020;33(6). doi:https://doi.org/10.1111/dth.14234
Mariana Alvares Penha, Hélio Amante Miot, Kasprzak M, Paulo Müller Ramos. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia. JAMA dermatology. 2024;160(6). doi:https://doi.org/10.1001/jamadermatol.2024.0284
Pirmez R, Salas-Callo CI. Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. Journal of the American Academy of Dermatology. 2020;82(1):e21-e22. doi:https://doi.org/10.1016/j.jaad.2019.08.084
Nascimento e Silva M, Ramos PM, Silva MR, Nascimento e Silva R, Barbosa Raposo NR. Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mg. Journal of the American Academy of Dermatology. Published online January 2022. doi:https://doi.org/10.1016/j.jaad.2022.01.017
Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. Journal of the American Academy of Dermatology. 2019;81(2):648-649. doi:https://doi.org/10.1016/j.jaad.2019.04.054
Panchaprateep R, Lueangarun S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatology and Therapy. 2020;10(6):1345-1357. doi:https://doi.org/10.1007/s13555-020-00448-x
Therianou A, Vincenzi C, Tosti A. How safe is prescribing oral minoxidil in patients allergic to topical minoxidil? Journal of the American Academy of Dermatology. Published online April 2020. doi:https://doi.org/10.1016/j.jaad.2020.04.027
Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: A randomized controlled trial. Journal of Cosmetic Dermatology. 2023;23(3). doi:https://doi.org/10.1111/jocd.16086
Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology. 2021;84(6):1644-1651. doi:https://doi.org/10.1016/j.jaad.2021.02.054
Sanabria B, Vanzela T de N, Miot HA, Müller Ramos P. Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients. Journal of the American Academy of Dermatology. 2021;84(4):1175-1178. doi:https://doi.org/10.1016/j.jaad.2020.11.035
Ong M, Do H, Ho B, Lipner SR. Low-dose oral minoxidil for androgenetic alopecia is not associated with clinically significant blood-pressure changes: A retrospective study. Journal of the American Academy of Dermatology. 2023;90(2):425-427. doi:https://doi.org/10.1016/j.jaad.2023.10.010
Andy G, John M, Mirna S, et al. Controversies in the treatment of androgenetic alopecia: The history of finasteride. Dermatologic Therapy. 2019;32(2):e12647. doi:https://doi.org/10.1111/dth.12647
Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ. Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Clinical, Cosmetic and Investigational Dermatology. 2023;Volume 16:1387-1406. doi:https://doi.org/10.2147/ccid.s385861
Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. Journal of Cosmetic Dermatology. 2021;20(12). doi:https://doi.org/10.1111/jocd.14537
Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of Suicidality and Depression With 5α-Reductase Inhibitors. JAMA internal medicine. 2017;177(5):683-691. doi:https://doi.org/10.1001/jamainternmed.2017.0089
Mazzarella G, Loconsole G, Cammisa G, Mastrolonardo G, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. Journal of Dermatological Treatment. 1997;8(3):189-192. doi:https://doi.org/10.3109/09546639709160517
Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int Journal of Clinical Pharmacology and Therapeutics. 2014;52(10):842-849. doi:https://doi.org/10.5414/cp202119
Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int Journal of Clinical Pharmacology and Therapeutics. 2016;54(01):19-27. doi:https://doi.org/10.5414/cp202467
Piraccini BM, Blume‐Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 2021;36(2):286-294. doi:https://doi.org/10.1111/jdv.17738
Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology. 2018;32(12):2257-2263. doi:https://doi.org/10.1111/jdv.15171
Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of Topical Combination of 0.25% Finasteride and 3% Minoxidil Versus 3% Minoxidil Solution in Female Pattern Hair Loss: A Randomized, Double-Blind, Controlled Study. American Journal of Clinical Dermatology. 2018;20(1):147-153. doi:https://doi.org/10.1007/s40257-018-0387-0
Asad N, Naseer M, Ghafoor R. Efficacy of Topical Finasteride 0.25% With Minoxidil 5% Versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. Journal of drugs in dermatology : JDD. 2024;23(11):1003-1008. doi:https://doi.org/10.36849/JDD.7826
Chandrashekar B, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride. Indian Dermatology Online Journal. 2015;6(1):17. doi:https://doi.org/10.4103/2229-5178.148925
Cervantes J, Perper M, Wong LL, et al. Effectiveness of Platelet-Rich Plasma for Androgenetic Alopecia: A Review of the Literature. Skin Appendage Disorders. 2018;4(1):1-11. doi:https://doi.org/10.1159/000477671
Getka B, Kinga Przyborowska, Mateusz Rukat, Michał Łata, Justyna Kwiecień, Katarzyna Wiejak. Platelet-rich plasma therapy in the treatment of androgenic alopecia – review. Journal of Education Health and Sport. 2024;53:187-197. doi:https://doi.org/10.12775/jehs.2024.53.014
Stevens J, Khetarpal S. Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. International Journal of Women’s Dermatology. 2018;5(1):46-51. doi:https://doi.org/10.1016/j.ijwd.2018.08.004
Cyran P, Jaroszyńska A, Filip Jaroszyński, et al. Platelet-Rich Plasma (PRP) in Hair Restoration Treatments: A Comprehensive Review of Existing Literature. Journal of Education Health and Sport. 2024;70:55220-55220. doi:https://doi.org/10.12775/jehs.2024.70.55220
Gentile P, Cole J, Cole M, et al. Evaluation of Not-Activated and Activated PRP in Hair Loss Treatment: Role of Growth Factor and Cytokine Concentrations Obtained by Different Collection Systems. International Journal of Molecular Sciences. 2017;18(2):408. doi:https://doi.org/10.3390/ijms18020408
Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R. What’s New in Therapy for Male Androgenetic Alopecia? American Journal of Clinical Dermatology. 2022;24. doi:https://doi.org/10.1007/s40257-022-00730-y
Cervelli V, Garcovich S, Bielli A, et al. The Effect of Autologous Activated Platelet Rich Plasma (AA-PRP) Injection on Pattern Hair Loss: Clinical and Histomorphometric Evaluation. BioMed Research International. 2014;2014:1-9. doi:https://doi.org/10.1155/2014/760709
Alves R, Grimalt R. Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia. Dermatologic Surgery. 2016;42(4):491-497. doi:https://doi.org/10.1097/dss.0000000000000665
Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Stem Cells Translational Medicine. 2015;4(11):1317-1323. doi:https://doi.org/10.5966/sctm.2015-0107
Li M, Qu K, Qiang L, Chen M, Bian D. Effectiveness of Platelet-Rich Plasma in the Treatment of Androgenic Alopecia: A Meta-Analysis. Aesthetic Plastic Surgery. 2023;48. doi:https://doi.org/10.1007/s00266-023-03603-9
Busanello EB, Turcatel E. Androgenic alopecia and dutasteride in hair mesotherapy: A short review. Our Dermatology Online. 2018;9(1):75-79. doi:https://doi.org/10.7241/ourd.20181.22
Ding Y, Wang C, Bi L, et al. Dutasteride for the Treatment of Androgenetic Alopecia: An Updated Review. Dermatology. Published online September 13, 2024:1-22. doi:https://doi.org/10.1159/000541395
Sobhy N, Aly H, El Shafee A, El Deeb M. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatology Online. 2013;4(1):40-45. doi:https://doi.org/10.7241/ourd.20131.08
Gupta AK, Shruthi Polla Ravi, Wang T, Talukder M, Starace M, Bianca Maria Piraccini. Systematic review of mesotherapy: a novel avenue for the treatment of hair loss. Journal of Dermatological Treatment. 2023;34(1). doi:https://doi.org/10.1080/09546634.2023.2245084
Abdallah M, El-Zawahry K, Besar H. Mesotherapy using Dutasteride-Containing Solution in Male Pattern Hair Loss: a Controlled Pilot Study. 2009;20:137-145.
Moftah N, Moftah N, Abd-Elaziz G, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. Journal of the European Academy of Dermatology and Venereology. 2012;27(6):686-693. doi:https://doi.org/10.1111/j.1468-3083.2012.04535.x
Saceda-Corralo D, Moustafa F, Moreno-Arrones Ó, Jaén-Olasolo P, Vañó-Galván S, Camacho F. Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice. Journal of drugs in dermatology: JDD. 2022;21(7):742-747. doi:https://doi.org/10.36849/JDD.6610
Delaney SW, Zhang P. Systematic review of low-level laser therapy for adult androgenic alopecia. Journal of Cosmetic and Laser Therapy. 2017;20(4):229-236. doi:https://doi.org/10.1080/14764172.2017.1400170
Mester E, Szende B, Gärtner P. [The effect of laser beams on the growth of hair in mice]. Radiobiologia, Radiotherapia. 1968;9(5):621-626.
Darwin E, Heyes A, Hirt PA, Wikramanayake TC, Jimenez JJ. Low-level laser therapy for the treatment of androgenic alopecia: a review. Lasers in Medical Science. 2018;33(2):425-434. doi:https://doi.org/10.1007/s10103-017-2385-5
S. Ntshingila, Ogheneochuko. Oputu, Afolake Arowolo, Khumalo NP. Androgenetic alopecia: an update. JAAD international. 2023;13:150-158. doi:https://doi.org/10.1016/j.jdin.2023.07.005
Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clinical drug investigation. 2009;29(5):283-292. doi:https://doi.org/10.2165/00044011-200929050-00001
Jimenez JJ, Wikramanayake TC, Bergfeld W, et al. Efficacy and Safety of a Low-level Laser Device in the Treatment of Male and Female Pattern Hair Loss: A Multicenter, Randomized, Sham Device-controlled, Double-blind Study. American Journal of Clinical Dermatology. 2014;15(2):115-127. doi:https://doi.org/10.1007/s40257-013-0060-6
Lanzafame RJ, Blanche RR, Bodian AB, Chiacchierini RP, Fernandez-Obregon A, Kazmirek ER. The growth of human scalp hair mediated by visible red light laser and LED sources in males. Lasers in Surgery and Medicine. 2013;45(8):487-495. doi:https://doi.org/10.1002/lsm.22173
Lanzafame RJ, Blanche RR, Chiacchierini RP, Kazmirek ER, Sklar JA. The growth of human scalp hair in females using visible red light laser and LED sources. Lasers in Surgery and Medicine. 2014;46(8):601-607. doi:https://doi.org/10.1002/lsm.22277
Esmat SM, Hegazy RA, Gawdat HI, et al. Low level light-minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: A randomized controlled study. Lasers in Surgery and Medicine. 2017;49(9):835-843. doi:https://doi.org/10.1002/lsm.22684
Qiu J, Yi Y, Jiang L, et al. Efficacy assessment for low-level laser therapy in the treatment of androgenetic alopecia: a real-world study on 1383 patients. Lasers in Medical Science. 2022;37(6):2589-2594. doi:https://doi.org/10.1007/s10103-022-03520-4
Gupta AK, Carviel J. Meta-analysis of photobiomodulation for the treatment of androgenetic alopecia. Journal of Dermatological Treatment. 2019;32(6):643-647. doi:https://doi.org/10.1080/09546634.2019.1688755
Visutjindaporn P, Parcharoen Y, Lueangarun S. Study of US FDA Clearance Home-Use Low Level Light/Laser Therapy for Androgenetic Alopecia. RSU International Research Conference 2020. Published online 2020:323-331. doi:https://doi.org/10.14458/RSU.res.2020.178
Weronika Kiełt, Kozłowska J, Broniec G, et al. Applications, impacts and consequences of botulinum toxin usage in medicine. Journal of Education Health and Sport. 2024;70:55709-55709. doi:https://doi.org/10.12775/jehs.2024.70.55709
82.SERWIK-TRANDASIR A, KANIA A, GONET M, et al. Wide range applications of botulinum toxin in medicine - literature review. Journal of Education, Health and Sport. 2023;45(1):203-214. doi:https://doi.org/10.12775/jehs.2023.45.01.014
Wang Y, Zhang H, Zheng Q, Tang K, Fang R, Sun Q. Botulinum toxin as a double‐edged sword in alopecia: A systematic review. Journal of Cosmetic Dermatology. 2020;19(10):2560-2565. doi:https://doi.org/10.1111/jocd.13647
Zhang L, Yu Q, Wang Y, Ma Y, Shi Y, Li X. A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. Dermatologic Therapy. 2019;32(4). doi:https://doi.org/10.1111/dth.12785
Shon U, Kim MH, Lee DY, Kim SH, Park BC. The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. Journal of the American Academy of Dermatology. 2020;83(6):1838-1839. doi:https://doi.org/10.1016/j.jaad.2020.04.082
Li L, Ma Q, Luo W, Ji J, Zhang X, Hong D. Efficacy of type A botulinum toxin treatment for androgenetic alopecia using ultrasound combined with trichoscopy. Skin Research and Technology. 2024;30(6). doi:https://doi.org/10.1111/srt.13803
Wael Mohamed Seoudy, Omnia Ahmed Metwally, Elfangary MM, Mohamed TM. Assessment of efficacy of different botulinum toxin A concentrations in the treatment of androgenetic alopecia assessed by dermoscopy. Journal of Cosmetic Dermatology. 2023;23(2). doi:https://doi.org/10.1111/jocd.15972
Zhou Y, Yu S, Zhao J, Feng X, Zhang M, Zhao Z. Effectiveness and Safety of Botulinum Toxin Type A in the Treatment of Androgenetic Alopecia. BioMed Research International. 2020;2020(1):1-7. doi:https://doi.org/10.1155/2020/1501893
English Jr. RS, Ruiz S. Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review. Skin Appendage Disorders. 2021;8(2):1-8. doi:https://doi.org/10.1159/000518574
Hussein RS, Dayel SB, Abahussein O. Botulinum Toxin A for Hair Loss Treatment: A Systematic Review of Efficacy, Safety, and Future Directions. JPRAS Open. 2023;38:296-304. doi:https://doi.org/10.1016/j.jpra.2023.09.006
Melo DF, Paulo Müller-Ramos, Fernanda R, et al. Efficacy of botulinum toxin in male androgenetic alopecia: A triple-blind, randomized clinical trial. Journal of the American Academy of Dermatology. 2024;91(5):996-998. doi:https://doi.org/10.1016/j.jaad.2024.07.1464
Chen X, Xiang H, Yang M. Topical cetirizine for treating androgenetic alopecia: A systematic review. Journal of Cosmetic Dermatology. 2022;21(11). doi:https://doi.org/10.1111/jocd.15309
Casale F, Nguyen C, Natasha Atanaskova Mesinkovska. Emerging medications. Procedures in Cosmetic Dermatology: Hair Restoration. Published online 2024:191-206. doi:https://doi.org/10.1016/b978-0-323-82921-2.00025-1
Cartwright M, Mazzetti A, Moro L, Rosette C, Gerloni M. A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia. Journal of the American Academy of Dermatology. 2019;81(4):AB13. doi:https://doi.org/10.1016/j.jaad.2019.06.087
Zhou X, Jiao Y, Zhang W, Li W. Androgens/Androgen Receptor in the Management of Skin Diseases. Journal of Biosciences and Medicines. 2022;10(12):180-200. doi:https://doi.org/10.4236/jbm.2022.1012015
Koralewicz MM, Szatkowska OA. Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum. 2024;10(3). doi:https://doi.org/10.5603/fd.101208
DuBois J, Bruce S, Stewart D, et al. Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial. Clinical, Cosmetic and Investigational Dermatology. 2021;Volume 14:1507-1517. doi:https://doi.org/10.2147/ccid.s319676
Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: An appraisal of new treatment approaches and overview of current therapies. Journal of the American Academy of Dermatology. 2018;78(1):15-24. doi:https://doi.org/10.1016/j.jaad.2017.04.1142
Yale K, Pourang A, Plikus MV, Mesinkovska NA. At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors. JAAD Case Reports. 2020;6(5):444-446. doi:https://doi.org/10.1016/j.jdcr.2020.02.026
Aclaris Therapeutics Announces Positive 6-Month Results from a Phase 2 Open-Label Clinical Trial of ATI-502 Topical in Patients with Androgenetic Alopecia (Male/Female Pattern-Baldness). BioSpace. Published June 18, 2019. https://www.biospace.com/aclaris-therapeutics-announces-positive-6-month-results-from-a-phase-2-open-label-clinical-trial-of-ati-502-topical-in-patients-with-androgenetic-alopecia-male-female-pattern-baldness
Mao Y, Liu P, Wei J, et al. Cell Therapy for Androgenetic Alopecia: Elixir or Trick? Stem cell reviews and reports. 2023;19(6):1785-1799. doi:https://doi.org/10.1007/s12015-023-10532-2
Katarzyna Krefft-Trzciniecka, Zuzanna Piętowska, Nowicka D, Szepietowski JC. Human Stem Cell Use in Androgenetic Alopecia: A Systematic Review. Cells. 2023;12(6):951-951. doi:https://doi.org/10.3390/cells12060951
Mao X, Hu W, Wu M, et al. Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic Alopecia. Journal of Medicinal Chemistry. Published online December 6, 2024. doi:https://doi.org/10.1021/acs.jmedchem.4c02226
Ma B, Liu D, Wang Z, et al. A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy. Journal of Medicinal Chemistry. 2024;67(12):10336-10349. doi:https://doi.org/10.1021/acs.jmedchem.4c00828
Copyright (c) 2025 Karolina Niewola, Martyna Różańska, Kacper Rozenberg, Justyna Stryjecka, Jędrzej Świercz
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
